Trial Profile
A Randomized Phase I/II Study of Bortezomib, Rituximab, Dexamethasone and Temsirolimus in Patients With Relapsed Waldenstrom's Macroglobulinemia and Relapsed/Refractory Mantle Cell, Follicular, Marginal Zone or Small Lymphocytic Lymphomas (Phase I), and Untreated/Relapsed Waldenstrom's Macroglobulinemia (Phase II)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Rituximab
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 04 Sep 2021 Status changed from discontinued to completed.
- 09 Apr 2021 Status changed from active, no longer recruiting to discontinued.
- 18 Nov 2013 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.